Review
Biochemistry & Molecular Biology
Binoy Yohannan, Binsah George
Summary: This article provides a comprehensive summary of the current management of Lymphoid Blast Crisis (BC), which is one of the most feared complications of chronic myeloid leukemia (CML). The incidence of BC has significantly decreased in the BCR-ABL tyrosine kinase inhibitor era, but there is still a need for novel therapies to improve the clinical outcomes of patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Indira Singaram, Ashutosh Sharma, Shashank Pant, Muyun Lihan, Mi-Jeong Park, Melissa Pergande, Pawanthi Buwaneka, Yusi Hu, Nadim Mahmud, You-Me Kim, Stephanie Cologna, Vladimir Gevorgyan, Irum Khan, Emad Tajkhorshid, Wonhwa Cho
Summary: Membrane lipids control the cellular activity of kinases containing the SH2 domain. In this study, new nonlipidic small molecule inhibitors of the lipid-SH2 domain interaction were developed to block the cellular activity of their host proteins. The research shows that targeting lipid-protein interaction is a powerful approach to developing new small molecule drugs.
NATURE CHEMICAL BIOLOGY
(2023)
Article
Oncology
Fadi G. Haddad, Hagop M. Kantarjian, Aram Bidikian, Elias J. Jabbour, Nicholas J. Short, Jing Ning, Lianchun Xiao, Naveen Pemmaraju, Courtney D. DiNardo, Tapan M. Kadia, Kayleigh R. Marx, Guillermo Garcia-Manero, Farhad Ravandi, Koji Sasaki, Ghayas C. Issa
Summary: Bariatric surgery has a negative impact on the treatment outcomes of patients with chronic myeloid leukemia, leading to lower early molecular response rates, longer time to achieve complete cytogenetic or major molecular responses, and lower survival rates.
Review
Pharmacology & Pharmacy
Gustavo P. Amarante-Mendes, Aamir Rana, Tarcila Santos Datoguia, Nelson Hamerschlak, Gabriela Brumatti
Summary: The constitutively active BCR-ABL1 tyrosine kinase plays a role in leukemia and initiates a complex signaling transduction cascade. Tyrosine kinase inhibitors have revolutionized the treatment of CML, but complete cure is not achieved. Other mechanisms exist in the later stages of the disease.
Article
Immunology
Qingya Cui, Peiqi Liang, Haiping Dai, Wei Cui, Mengjie Cai, Zixuan Ding, Qinfen Ma, Jia Yin, Zheng Li, Sining Liu, Liqing Kang, Li Yao, Jiannong Cen, Hongjie Shen, Mingqing Zhu, Lei Yu, Depei Wu, Xiaowen Tang
Summary: Resistance to TKIs and chemotherapy in CML-BP may be overcome by CAR-T-38 cell therapy, targeting CD38 antigen, leading to significant therapeutic responses.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Jorge Cortes, Fabian Lang
Summary: CML is driven by the BCR-ABL1 fusion protein, making the ATP binding site of ABL1 an optimal target for TKIs. Despite improvements in prognosis, patients often fail treatment and require new therapeutic options.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Cell & Tissue Engineering
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Summary: CML is driven by the BCR-ABL1 oncoprotein, and TKI therapy has been successful. However, mechanisms leading to resistance and disease progression in CML LSCs call for targeted therapies to eradicate them.
STEM CELL RESEARCH & THERAPY
(2021)
Article
Chemistry, Multidisciplinary
Yangyang Du, Mingda Han, Kunxia Cao, Qing Li, Jiuxia Pang, Liping Dou, Shujun Liu, Zhan Shi, Fei Yan, Shouhua Feng
Summary: Reprogramming the m(6)A landscape using gold nanorods selectively taken up by leukemia cells inhibits leukemia cell growth by disrupting redox balance and inducing ferroptosis. The nanorods abrogate endogenous m(6)A demethylase activity, leading to global m(6)A hypomethylation and post-transcriptional regulation of downstream genes. Combination treatment with the nanorods and tyrosine kinases inhibitors synergistically overcomes m(6)A-mediated TKI resistance and enhances immunotherapy outcome in leukemia.
Review
Oncology
Yilin Chen, Jing Zou, Fanjun Cheng, Weiming Li
Summary: The therapeutic landscape for chronic myeloid leukemia has improved significantly with the approval of tyrosine kinase inhibitors. Most patients experience normal life expectancy with optimal responses to TKIs, but relapse after discontinuation hinders attempts at treatment-free remission. New monitoring methods and strategies targeting leukemic stem cells are being explored to address this challenge.
FRONTIERS IN ONCOLOGY
(2021)
Review
Health Care Sciences & Services
Carolina Alarcon-Payer, Maria Del Mar Sanchez Suarez, Alicia Martin Roldan, Jose Manuel Puerta Puerta, Alberto Jimenez Morales
Summary: Malignant hematological diseases are caused by acquired mutations or rearrangements in cell replication processes; personalized treatment targeting new recurrent mutations is important in AML; the management of CML patients has shifted towards targeted therapy with tyrosine kinase inhibitors.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Alona Telerman, Galit Granot, Chiya Leibovitch, Osnat Yarchovsky-Dolberg, Adi Shacham-Abulafia, Shirly Partouche, Moshe Yeshurun, Martin H. Ellis, Pia Raanani, Ofir Wolach
Summary: Neutrophil extracellular traps (NETs) are increased in chronic myeloid leukemia (CML) and certain drugs used to treat CML (tyrosine kinase inhibitors-TKIs) further increase NET formation, suggesting a possible link between CML, TKIs, and vascular toxicity.
Letter
Oncology
Yunxin Zeng, Xinyu Zhang, Dongjun Lin, Xiaohui Feng, Yuye Liu, Zhengwen Fang, Weijian Zhang, Yu Chen, Meng Zhao, Jun Wu, Linjia Jiang
Summary: This study revealed that hypoxia environment increases lysosomes in leukemia cells, which in turn reduces the effectiveness of chemotherapy drugs. By developing a novel nanomedicine targeting lysosomes, the researchers were able to enhance the chemotherapy outcome in leukemia. This new approach shows promising results in overcoming chemoresistance in myeloid leukemia.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Mei-Tsen Chen, Shih-Tsung Huang, Chih-Wan Lin, Bor-Sheng Ko, Wen-Jone Chen, Huai-Hsuan Huang, Fei-Yuan Hsiao
Summary: This study found that patients with chronic myeloid leukemia (CML) treated with nilotinib had a significantly higher risk of developing vascular adverse events (VAEs) compared to those treated with imatinib, while dasatinib users also showed a trend for VAE development. Nilotinib usage, older age, and history of cerebrovascular diseases were identified as significant risk factors for VAEs.
Review
Biotechnology & Applied Microbiology
Sara De Santis, Cecilia Monaldi, Manuela Mancini, Samantha Bruno, Michele Cavo, Simona Soverini
Summary: Protein kinases play crucial roles in cancer pathogenesis and treatment, but resistance remains a challenge. Overcoming resistance requires the utilization of main mechanisms and strategies, with chronic myeloid leukemia serving as a model disease for other cancer treatments.
ONCOTARGETS AND THERAPY
(2022)
Article
Pharmacology & Pharmacy
Massimo Breccia, Gioia Colafigli, Emilia Scalzulli, Maurizio Martelli
Summary: Tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for CML patients, but resistance and intolerance can still be issues. Asciminib, an allosteric inhibitor, shows promise as a third-line treatment option, particularly for patients with the T315I mutation.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Critical Care Medicine
Swee Han Lim, Sze Jet Aw, May Anne Cheong, Jenny Chew, Ai Choo Ler, Li Ping Yong, Yiong Huak Chan, Ma Thin Mar Win, Nagamal Suppiah
Article
Obstetrics & Gynecology
Sun Kuie Tay, May Anne Cheong
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY
(2014)
Letter
Urology & Nephrology
Cynthia Ciwei Lim, Khin Zar Li Lwin, May Anne Cheong, Kamaraj Kanagasabapathy, Chandramouli Nagarajan, Alwin Loh
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2020)
Letter
Hematology
May A. Cheong, Yen-L. Chee, Heng J. Ng, Wei-Y. Jen
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2020)
Article
Multidisciplinary Sciences
Chuen Wen Tan, Jing Yuan Tan, Wan Hui Wong, May Anne Cheong, Ian Matthias Ng, Edwin Philip Conceicao, Jenny Guek Hong Low, Heng Joo Ng, Lai Heng Lee
Summary: Thrombotic rates did not differ significantly between COVID-19 and non-CoV-2-RV patients, with low occurrence overall. Hypercoagulability in COVID-19 is a dynamic process, most pronounced in severe cases, detectable by CWA. Individually tailored thromboprophylaxis may be more suitable for hospitalized COVID-19 patients instead of universal pharmacological thromboprophylaxis.
SCIENTIFIC REPORTS
(2021)
Letter
Hematology
Jing Yuan Tan, Chuen Wen Tan, Wan Hui Wong, May Anne Cheong, Lai Heng Lee, Shirin Kalimuddin, Jenny Guek Hong Low, Heng Joo Ng
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2022)
Editorial Material
Hematology
May Anne Cheong, Kenneth Michael Chew
Summary: Bone cement implantation syndrome (BCIS) is a rare and potentially fatal perioperative complication that can lead to intracardiac clot and saddle pulmonary artery embolus.
THROMBOSIS AND HAEMOSTASIS
(2022)
Article
Hematology
May Anne Cheong, Chuen Wen Tan, Wan Hui Wong, Ming Chai Kong, Edmund See, Shu Hui Yeang, Sei Keng Koh, Yuan Tying Shim, Lai Heng Lee, Heng Joo Ng
Summary: This study evaluates the correlation between aPTT-based clot waveform analysis (CWA) and CAT parameters in warfarin-treated patients with varying INR levels. The results show a significant correlation between peak thrombin and all CWA parameters, as well as a significant correlation between endogenous thrombin potential (ETP) and most CWA parameters. Adjusted CWA improves the correlation with CAT.
Article
Endocrinology & Metabolism
Aye Chan Maung, May Anne Cheong, Ying Ying Chua, Daphne Su-Lyn Gardner
Summary: Thyroid storm is a rare but potentially life-threatening complication associated with excessive thyroid hormone action, leading to a hypercoagulable state and extensive thromboembolism. The role of anticoagulation in thyroid storm remains controversial, but routine prophylactic anticoagulation should be considered in those patients to prevent severe thromboembolic complications.
ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS
(2021)
Review
Medicine, General & Internal
May Anne Cheong, Catherine Swee Kian Tay
SINGAPORE MEDICAL JOURNAL
(2014)
Article
Oncology
Xiaofan Pu, Chaolei Zhang, Guoping Ding, Hongpeng Gu, Yang Lv, Tao Shen, Tianshu Pang, Liping Cao, Shengnan Jia
Summary: This study demonstrated the potential utility of the sEV-miRNA d-signature in the diagnosis of PDAC via machine learning methods. A novel sEV biomarker, miR-664a-3p, was identified for the diagnosis of PDAC. It can also potentially promote angiogenesis and metastasis, provide insight into PDAC pathogenesis, and reveal novel regulators of this disease.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Jiaping Wang, Zhijuan Xu, Yanli Lai, Yanli Zhang, Ping Zhang, Qitian Mu, Shujun Yang, Yongcheng Sun, Lixia Sheng, Guifang Ouyang
Summary: This study demonstrates the significance of PD-1 in EBV-infected lymphoma cells. Silencing PD-1 enhances the tumor targeting effect of EBV-specific killer T cells on B lymphocytes and attenuates the immune escape effect.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Qiliang Peng, Jialong Tao, Yingjie Xu, Yi Shen, Yong Wang, Yang Jiao, Yiheng Mao, Yaqun Zhu, Yulong Liu, Ye Tian
Summary: This study investigates the potential role of lipid metabolism-associated genes (LMAGs) in neoadjuvant chemoradiotherapy (nCRT) and immunotherapy for rectal cancer. The results suggest that the SREBF2 gene is a highly predictive factor for nCRT in rectal cancer and is associated with favorable prognosis. SREBF2 is also closely associated with immune cell infiltration and immunotherapy-related genes.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Shiquan Li, Nan Zhang, Yongping Yang, Tongjun Liu
Summary: This study investigated the potential molecular mechanism of SPDEF in immune evasion of colorectal cancer (CRC) and found that it suppresses immune evasion by activating CCL28 through the modulation of M2 polarization of macrophages. These findings provide a new research direction and potential therapeutic target for immunotherapy in CRC.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Manas Sehgal, Soundharya Ramu, Joel Markus Vaz, Yogheshwer Raja Ganapathy, Srinath Muralidharan, Sankalpa Venkatraghavan, Mohit Kumar Jolly
Summary: This study investigates the relationship between gene expression patterns and phenotypic plasticity and heterogeneity in colorectal cancer (CRC). The results demonstrate the interconnectedness between different Consensus Molecular Subtypes (CMS) of CRC and specific phenotypes such as epithelial and mesenchymal characteristics. Additionally, the study reveals correlations between metabolic pathways and phenotypic scores, as well as between PD-L1 activity and mesenchymal phenotype. Single-cell RNA sequencing analysis further confirms the heterogeneity of different CMS subtypes. These findings have important implications for understanding CRC heterogeneity and developing targeted therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yutong Zou, Siyao Guo, Yan Liao, Weidong Chen, Ziyun Chen, Junkai Chen, Lili Wen, Xianbiao Xie
Summary: This study found that ceramide metabolism is associated with the progression and clinical outcome of osteosarcoma by analyzing data from osteosarcoma patients. The gene ST3GAL1 plays an important role in osteosarcoma, regulating the tumor immune microenvironment and affecting T cell function. It may become a new target for the treatment of osteosarcoma.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Chuanhui Chen, Mengzhi Wan, Xiong Peng, Qing Zhang, Yu Liu
Summary: This study examines the function and mechanism of the ceRNA network centered around GPR37 in LUAD. The findings show that high expression of GPR37 in LUAD tissue samples is associated with poor prognosis, and it may regulate the expression of downstream target genes by competitively binding to lncRNA DLEU1 and miR-4458.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Junping Li, Hong Hu, Jinping He, Yuling Hu, Manting Liu, Bihui Cao, Dongni Chen, Xiaodie Ye, Jian Zhang, Zhiru Zhang, Wen Long, Hui Lian, Deji Chen, Likun Chen, Lili Yang, Zhenfeng Zhang
Summary: Sequential administration of CDC7 inhibitor XL413 after carboplatin enhances the chemotherapeutic effect of carboplatin on ovarian cancer cells, possibly by inhibiting homologous recombination repair activity and increasing the accumulation of chemotherapy-induced DNA damage.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Madison Catalanotto, Joel Markus Vaz, Camille Abshire, Reneau Youngblood, Min Chu, Herbert Levine, Mohit Kumar Jolly, Ana -Maria Dragoi
Summary: The study demonstrates that loss of FLASH in cancer cells leads to a hybrid E/M phenotype with high epithelial scores, suggesting FLASH acts as a repressor of the epithelial phenotype. Additionally, FLASH expression is inversely correlated with the epithelial score and subsets of mesenchymal markers are distinctly up-regulated in FLASH, NPAT, or SLBP-depleted cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Xiaorui Wang, Na Li, Minying Zheng, Yongjun Yu, Shiwu Zhang
Summary: Adipocytes are derived from pluripotent mesenchymal stem cells and histone modifications play a key role in their differentiation. Recent studies have shown that cancer stem cells can differentiate into adipocytes, reducing the malignancy of cancer cells.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Hana Q. Sadida, Alanoud Abdulla, Sara Al Marzooqi, Sheema Hashem, Muzafar A. Macha, Ammira S. Al-Shabeeb Akil, Ajaz A. Bhat
Summary: Cancer heterogeneity and drug resistance are major obstacles to effective cancer treatment, and epigenetic modifications play a pivotal role in these processes. This review explores essential epigenetic modifications, including DNA methylation, histone modifications, and chromatin remodeling, and discusses their complex contributions to cancer biology. However, the interplay of epigenetic and genetic changes in cancer cells presents unique challenges that must be addressed to fully exploit the potential of epigenetic modifications.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Pedro De Marchi, Leticia Ferro Leal, Luciane Sussuchi da Silva, Rodrigo de Oliveira Cavagna, Flavio Augusto Ferreira da Silva, Vinicius Duval da Silva, Eduardo C. A. da Silva, Augusto O. Saito, Vladmir C. Cordeiro de Lima, Rui Manuel Reis
Summary: The TIS and IFN-gamma signatures are predictive biomarkers for identifying NSCLC patients who could potentially benefit from immune checkpoint inhibitor therapies.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Giovanni Marchi, Anna Rajavuori, Mai T. N. Nguyen, Kaisa Huhtinen, Sinikka Oksa, Sakari Hietanen, Sampsa Hautaniemi, Johanna Hynninen, Jaana Oikkonen
Summary: The study shows that ctDNA can adequately represent high-grade serous ovarian carcinoma (HGSC), and the mutations observed at relapse suggest personalized therapy options.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Yuncang Yuan, Jiawei Fan, Dandan Liang, Shijie Wang, Xu Luo, Yongjie Zhu, Nan Liu, Tingxiu Xiang, Xudong Zhao
Summary: This study demonstrates that csGRP78-directed CAR-T cells can selectively kill pancreatic cancer cells, and the combination with chemotherapy enhances cytotoxicity.
TRANSLATIONAL ONCOLOGY
(2024)
Article
Oncology
Niyati Piplani, Tanusri Roy, Neha Saxena, Shamik Sen
Summary: The glycocalyx, a protective barrier surrounding cells, has been found to play a role in cancer cell proliferation, survival, and metastasis. However, its function in maintaining DNA/nuclear integrity during migration through dense matrices has not been explored. This study shows that the bulkiness of the glycocalyx is inversely associated with nuclear stresses, and highlights its mechanical role in shielding migration-associated stresses.
TRANSLATIONAL ONCOLOGY
(2024)